AMPK-derived peptides reduce blood glucose levels but lead to fat retention in the liver of obese mice

Journal of Endocrinology

Volumn 221, Issue 1, 2014, Pages 89-99

  Chapnik, Nava ^a   Genzer, Yoni ^a   Ben Shimon, Avraham ^a   Niv, Masha Y ^a   Froy, Oren ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

AMPK; Metabolism; Obesity; Peptides

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ACETIC ACID DERIVATIVE; ACETYL PEPTIDE; ADIPONECTIN; AGENTS AFFECTING METABOLISM; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LEPTIN; LIPID EMULSION; METFORMIN; MYRISTOYL PEPTIDE; PEPTIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL DIFFERENTIATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG DESIGN; ENZYME ACTIVATION; ENZYME ACTIVE SITE; EX VIVO STUDY; FATTY ACID SYNTHESIS; FOOD INTAKE; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID LIVER LEVEL; LIPID STORAGE; LIVER CELL; LIVER WEIGHT; MALE; MOLECULAR DYNAMICS; MOUSE; MYOBLAST; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; TISSUE CULTURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

AMPK; METABOLISM; OBESITY; PEPTIDES;

ADIPOSE TISSUE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOOD GLUCOSE; DOWN-REGULATION; FATS; HUMANS; INSULIN; LIVER; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, OBESE; OBESITY; PEPTIDES; PROTEIN STRUCTURE, TERTIARY;

EID: 84897871640     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-13-0625     Document Type: Article

References (34)

1. Arora PS & Ansari AZ 2009 Chemical biology: a Notch above other inhibitors. Nature 462 171-173.
2. Batandier C, Guigas B, Detaille D, El-Mir MY, Fontaine E, Rigoulet M & Leverve XM 2006 The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin. Journal of Bioenergetics and Biomembranes 38 33-42.
3. Ben-Shimon A, Shalev DE & Niv MY 2013 Protonation States in molecular dynamics simulations of peptide folding and binding. Current Pharmaceutical Design 19 4173-4181.
4. Booth B & Zemmel R 2004 Prospects for productivity. Nature Reviews. Drug Discovery 3 451-456.
5. Carling D,Mayer FV, Sanders MJ & Gamblin SJ 2011 AMP-activated protein kinase: nature's energy sensor. Nature Chemical Biology 7 512-518.
6. Cheng S & Niv MY 2010 Molecular dynamics simulations and elastic network analysis of protein kinase B (Akt/PKB) inactivation. Journal of Chemical Information and Modeling 50 1602-1610.
7. Daval M, Diot-Dupuy F, Bazin R, Hainault I, Viollet B, Vaulont S, Hajduch E, Ferre P & Foufelle F 2005 Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. Journal of Biological Chemistry 280 25250-25257.
8. Dror RO, Dirks RM, Grossman JP, Xu H & Shaw DE 2012 Biomolecular simulation: a computational microscope for molecular biology. Annual Review of Biophysics 41 429-452.
9. Hardie DG 2007 AMP-activated protein kinase as a drug target. Annual Review of Pharmacology and Toxicology 47 185-210.
10. Hardie DG 2011 Signal transduction: how cells sense energy. Nature 472 176-177.
11. Harvey S, Tan RKZ & Cheatham TE 1998 The flying ice cube: velocity rescaling in molecular dynamics leads to violation of energy equipartition. Journal of Computational Chemistry 19 726-740.
12. Henriksen BS, Curtis ME, Fillmore N, Cardon BR, Thomson DM & Hancock CR 2013 The effects of chronic AMPK activation on hepatic triglyceride accumulation and glycerol 3-phosphate acyltransferase activity with high fat feeding. Diabetology & Metabolic Syndrome 5 29.
13. Kahn BB, Alquier T, Carling D & Hardie DG 2005 AMP-activated protein kinase: ancient energy gauge provides clues tomodern understanding of metabolism. Cell Metabolism 1 15-25.
14. Mack E, Ziv E, Reuveni H, Kalma R, Niv MY, Jorns A, Lenzen S & Shafrir E 2008 Prevention of insulin resistance and b-cell loss by abrogating PKC epsilon-induced serine phosphorylation of muscle IRS-1 in Psammomys obesus. Diabetes/Metabolism Research and Reviews 24 577-584.
15. Merrill JF, Thomson DM, Hardman SE, Hepworth SD, Willie S & Hancock CR 2012 Iron deficiency causes a shift in AMP-activated protein kinase (AMPK) subunit composition in rat skeletal muscle. Nutrition and Metabolism 9 104.
16. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, Mu J, Foufelle F, Ferre P, Birnbaum MJ et al. 2004 AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428 569-574.
17. Niesler CU, Myburgh KH & Moore F 2007 The changing AMPK expression profile in differentiating mouse skeletal muscle myoblast cells helps confer increasing resistance to apoptosis. Experimental Physiology 92 207-217.
18. Nissen SE & Wolski K 2007 Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine 356 2457-2471.
19. Niv MY, Rubin H, Cohen J, Tsirulnikov L, Licht T, Peretzman-Shemer A, Cna'an E, Tartakovsky A, Stein I, Albeck S et al. 2004 Sequence-based design of kinase inhibitors applicable for therapeutics and target identification. Journal of Biological Chemistry 279 1242-1255.
20. Onufriev A, Bashford D & Case DA 2004 Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins 55 383-394.
21. Pronk S, Pall S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, Shirts MR, Smith JC, Kasson PM, van der Spoel D et al. 2013 GROMACS 4.5: a highthroughput and highly parallel open source molecular simulation toolkit. Bioinformatics 29 845-854.
22. Rizzuti B & Daggett V 2013 Using simulations to provide the framework for experimental protein folding studies. Archives of Biochemistry and Biophysics 531 128-135.
23. Rubinstein M & Niv MY 2009 Peptidic modulators of protein-protein interactions: progress and challenges in computational design. Biopolymers 91 505-513.
24. Sajan MP, Ivey RA III & Farese RV 2013 Metformin action in human hepatocytes: coactivation of atypical protein kinase C alters 50-AMP-activated protein kinase effects on lipogenic and gluconeogenic enzyme expression. Diabetologia 56 2507-2516.
25. Sanders MJ, Grondin PO, Hegarty BD, Snowden MA & Carling D 2007 Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochemical Journal 403 139-148.
26. Scannell JW, Blanckley A, Boldon H & Warrington B 2012 Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews. Drug Discovery 11 191-200.
27. Scholz R, Suter M, Weimann T, Polge C, Konarev PV, Thali RF, Tuerk RD, Viollet B, Wallimann T, Schlattner U et al. 2009 Homo-oligomerization and activation of AMP-activated protein kinase are mediated by the kinase domain aG-helix. Journal of Biological Chemistry 284 27425-27437.
28. Stapleton D,Mitchelhill KI, Gao G, Widmer J,Michell BJ, Teh T, House CM, Fernandez CS, Cox T, Witters LA et al. 1996 Mammalian AMP-activated protein kinase subfamily. Journal of Biological Chemistry 271 611-614.
29. Tomita K, Tamiya G, Ando S, Kitamura N, Koizumi H, Kato S, Horie Y, Kaneko T, Azuma T, Nagata H et al. 2005 AICAR, an AMPK activator, has protective effects on alcohol-induced fatty liver in rats. Alcoholism, Clinical and Experimental Research 29 240S-245S.
30. Viollet B, Foretz M, Guigas B, Horman S, Dentin R, Bertrand L, Hue L & Andreelli F 2006 Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. Journal of Physiology 574 41-53.
31. Wells JA & McClendon CL 2007 Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450 1001-1009.
32. Wexler ID, Niv MY & Reuveni H 2005 Sequence-based protein kinase inhibition: applications for drug development. Biotechniques 39 575-576.
33. Yoon MJ, Lee GY, Chung J-J, Ahn YH, Hong SH & Kim JB 2006 Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor (a). Diabetes 55 2562-2570.
34. Zimmet P, Alberti KG & Shaw J 2001 Global and societal implications of the diabetes epidemic. Nature 414 782-787.